Last updated: February 24, 2026
What is NDC 66869-0104?
NDC 66869-0104 pertains to a specific pharmaceutical product, in this case, the Xyrem (sodium oxybate), used primarily to treat narcolepsy with cataplexy and excessive daytime sleepiness. It is a controlled substance with a high potential for abuse and dependence.
Market Overview
Market Size
The Xyrem market has experienced sustained growth driven by increased diagnosis of narcolepsy and off-label use in other sleep disorders. As of 2022, the US market for sodium oxybate drugs exceeds \$900 million, with Xyrem accounting for approximately 85% of sales.
Key Market Drivers
- Increased awareness of narcolepsy symptoms.
- Expanded indications for use in other sleep-related conditions.
- Strong patent protection and pipeline activity.
- Pricing sophistication due to regulatory oversight and insurance coverage.
Competitive Landscape
Application of Xyrem is limited to Orphan Drug designation, restricting generic competition and aiding pricing stability.
| Competitors |
Market Share (2022) |
Key Differentiators |
| Xyrem (Jazz Pharmaceuticals) |
85% |
Established market leader |
| Upcoming generics (pending approval) |
10% |
Price pressure potential |
| Alternative therapies |
5% |
Different mechanism or off-label use |
Regulatory Environment
The medication is classified as Schedule III under the Controlled Substances Act, with strict prescribing and distribution requirements.
Pricing Dynamics and Projections
Current Price Point
In the US, wholesale acquisition cost (WAC) for Xyrem averages \$1,000 per 30 mL bottle. Insurance reimbursement plans largely cover this, with out-of-pocket costs dependent on patient co-pay tiers.
| Pricing Variables |
Details |
| Average Wholesale Price (AWP) |
Approximately \$1,200 per bottle |
| Insurance Reimbursement Rate |
80-90%, depending on plan |
| Patient Co-pay |
\$50–\$300 per month, based on coverage |
Factors Influencing Price Trends
- Regulatory Changes: Tightening of distribution controls could increase costs.
- Patent Expiry: No imminent patent expiration expected; patent protection extends into the late 2020s.
- Generic Entry: Pending approval of generics could reduce prices by 20-30%, but current barriers slow ingress.
- Development of Biosimilars: Not applicable, due to drug being a small molecule.
- Market Penetration in New Regions: Expansion into Europe and Asia could moderate price increases but typically introduces variability.
Short-term Price Projections (Next 3-5 Years)
- Stable Pricing: Anticipated, with minor fluctuations driven by inflation and regulation.
- Potential Price Reduction: Likely 15-20% over five years if generics enter the US market.
- Premium Pricing Scenario: If new proprietary formulations or delivery mechanisms approve, premiums could persist.
Long-term Price Outlook (Beyond 5 Years)
- Gradual decline in price tied to biosimilar and generic competition.
- Market consolidation may sustain higher prices if restrictions tighten.
- Global expansion could introduce higher prices in emerging markets due to regulatory and distribution costs.
Revenue Projections
| Year |
Revenue (USD) |
Assumptions |
| 2022 |
\$900 million |
Stable sales driven by market penetration |
| 2023 |
\$880 million |
Slight decline from patent-related exclusivity |
| 2025 |
\$750 million |
Revenue impacted by generic competition |
| 2027 |
\$650 million |
Continued erosion, with further generics available |
| 2030 |
\$600 million |
Market stabilization at lower price levels |
Key Market Risks
- Regulatory scrutiny might restrict distribution channels.
- Patent challenges could open markets for generics sooner.
- Market saturation and off-label use limitations could curb growth.
- Pricing pressures from managed care entities and policy shifts.
Summary
Xyrem (NDC 66869-0104) maintains a dominant market position with high pricing stability in the US due to patent protection and regulatory barriers. Short-term projections depict stable prices with potential declines as generic products threaten market value. Long-term outlook depends on regulatory developments, market expansion, and competitive pressures.
Key Takeaways
- The US market value exceeds \$900 million annually for NDC 66869-0104.
- Current pricing averages \$1,000 per 30 mL bottle, with insurance reimbursement making patient costs manageable.
- Price erosion of 15-20% expected over five years due to generics.
- Patent protection and regulatory controls will sustain current pricing levels into the mid-2020s.
- International expansion remains a key growth driver but involves variable pricing environments.
FAQs
1. When does the patent for Xyrem expire?
Patent protection extends into the late 2020s, delaying generic entry.
2. What is the likelihood of generic competition?
Pending FDA approval, with approval likely within the next 1-2 years, though market entry may face hurdles due to distribution restrictions.
3. How does insurance coverage impact pricing?
Insurance covers approximately 80-90% of drug costs, reducing out-of-pocket expenses but maintaining high wholesale prices.
4. Are biosimilars relevant for sodium oxybate?
No, biosimilars are not applicable as the drug is a small molecule, not a biologic.
5. What regional markets show the greatest growth potential?
Europe and Asia are primary targets but face different regulatory and reimbursement landscapes affecting pricing.
References
[1] IQVIA. (2022). Pharmaceutical Market Reports.
[2] FDA. (2022). Approved Drugs Database.
[3] Jazz Pharmaceuticals. (2022). Annual Financial Reports.
[4] U.S. Department of Justice. (2018). Controlled Substances Act Regulations.
[5] Reuters. (2022). Market dynamics of sleep disorder medications.
